BeOne Medicines (NasdaqGS:ONC) is back in focus after a cluster of analyst upgrades to Strong Buy and fresh ASCO 2026 data on three solid tumor candidates, paired with plans for multiple registrational trials.

Despite upbeat ASCO 2026 headlines and analyst upgrades, BeOne’s 1 month share price return is down 13.46% and the year to date share price return is down 13.16%, while the 1 year total shareholder return is 5.57%. This suggests long term holders have still come out ahead.

If this kind of oncology pipeline has your attention, it can be worth scanning for other cancer focused developers using the Simply Wall St screener for 39 healthcare AI stocks

With BeOne trading at US$270.10 and sitting about 48% below the average analyst price target, plus a large implied discount to some intrinsic value estimates, investors have to ask: is there a bargain here, or is the market already pricing in future growth?

Most Popular Narrative: 34.4% Undervalued

BeOne’s most followed valuation narrative pegs fair value at $411.51 per share, well above the last close at $270.10, putting a spotlight on how much future growth is being baked into those models.

BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5 to $5.3B) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA, supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.

Want to see what sits behind that valuation gap? The narrative leans on double digit revenue growth, rising margins, and a future earnings base that looks very different to today. The twist is how high the implied future earnings multiple still runs compared to the wider biotech sector.

Result: Fair Value of $411.51 (UNDERVALUED)

However, this story can change quickly if competition in BTK inhibitors bites into BRUKINSA or if regulatory pricing pressure squeezes the higher margin outlook that analysts are assuming.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Earnings Multiple Sends a Different Signal

Those fair value models suggest upside, but the market is pricing BeOne very differently. The stock trades on a P/E of 58.5x, compared with 32.2x for peers and 16.6x for the wider US Biotechs industry, while the fair ratio sits at 32.5x. That gap points to meaningful valuation risk if sentiment cools.

Before leaning on any single narrative, it is worth stress testing these earnings-based signals against a fuller breakdown of how the current price stacks up to the fair ratio and peer group, and what would need to change in the business for that premium to hold. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment this mixed, it pays to look at the numbers yourself and decide quickly whether the reward potential justifies the risks. To see what is driving optimism on the upside, review the 4 key rewards

Looking for more investment ideas?

If BeOne has raised your curiosity, do not stop here; broaden your watchlist with focused stock ideas that match different goals using the Simply Wall St screener.

• Target potential value opportunities by scanning companies highlighted in the 49 high quality undervalued stocks and see which ones fit your return expectations.
• Prioritize resilience by checking out stocks in the 61 resilient stocks with low risk scores, where business quality and risk scores are central to the selection.
• Explore potential standouts by filtering through the screener containing 21 high quality undiscovered gems to see which companies align with your criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.